3.3. screening. despite growing interest patients clinicians rcc screening programmes, relative lack studies reporting efficacy, cost-effectiveness, optimal modality rcc screening. urinary dipstick inadequate screening tool due low sensitivity specificity. also incidence rcc non-visible haematuria low; 0.58% . clinically validated urinary serum biomarkers yet identified. computed tomography cannot recommended due cost, radiation dose increased potential incidental findings. ultrasound (us) could used acceptable sensitivity specificity, although tumour size operator dependant. major barriers population screening include relatively low prevalence disease, potential false positives over-diagnosis slow-growing kidney tumours. targeting high-risk individuals and/or combining detection rcc routine health screenings may represent pragmatic options improve cost-effectiveness reduce potential harms rcc screening [18-20]. targeting high-risk patient groups e.g., end-stage renal disease (esrd) associated 10-fold increased risk developing rcc may also valid approach (see section 3.5.2) . currently evidence support primary screening general population. 3.3.1. summary evidence recommendations epidemiology, aetiology screening summary evidenceleseveral verified risk factors identified including smoking, obesity hypertension. considered definite risk factors rcc.2athere evidence support primary screening rcc.4 recommendationsstrength ratingincrease physical activity, eliminate cigarette smoking obese patients reduce weight primary preventative measures decrease risk rcc.strongdo routinely screen population primary rcc.weak